Clinical Trials Browser

Phase 2 × OTHER × Pancreatic Cancer Resectable × Clear all

NCT06722911 2024-12-09

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Cancer Resectable

NCT04224402 2023-02-15

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Phase 2 Completed

Gastrointestinal

Pancreatic Cancer Resectable

NCT03344172 2020-05-14

17-134

Phase 2 Terminated

32 enrolled 14 charts

Gastrointestinal

Pancreatic Cancer Resectable